Immunoglobulin News and Research

RSS

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

A new preprint posted to the bioRxiv server demonstrates that similar mucins and mucin-like proteins cannot only suppress HIV-1 infectivity via blockage of viral attachment to the host cells but can block infection by multiple enveloped viruses.

4 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

Researchers develop rapid COVID-19 diagnostic test affordable for low-income families

A test that detects antibodies to the novel coronavirus in 10 minutes and costs only a fifth of the market average has been developed by researchers at the University of São Paulo's São Carlos Chemistry Institute and Brazilian startup Biolinker, with São Paulo Research Foundation - FAPESP's support.

2 Feb 2021

Previous SARS-CoV-2 infection may negate need for two vaccine doses

Researchers in the United States have shown that two doses of vaccine may not be necessary to protect against coronavirus disease 2019 (COVID-19) among people who have already been infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

New platform for detecting and monitoring SARS-CoV-2 antibody responses

Researchers in the U.S. have released a new study that describes a powerful but inexpensive tool designed to detect and monitor specific antibodies to SARS-CoV-2 over time.

1 Feb 2021

Fetal and neonatal therapy combination may lessen the aftereffects of congenital CMV infection

A cross-institutional research group has revealed for the first time in the world that infants with symptomatic congenital cytomegalovirus (CMV) infection who were treated with a combination of immunoglobulin fetal therapy and neonatal therapy with antiviral drugs were less likely to experience the severe aftereffects associated with the infection than those who only received the neonatal therapy.

28 Jan 2021

Moderna vaccine shows robust suppression of SARS-CoV-2 infection in animal model

Researchers have demonstrated that the prime or prime-boost vaccination of Moderna vaccine in hamsters induced robust neutralizing antibodies, ameliorated weight loss, and suppressed SARS-CoV-2 replication in the airways.

28 Jan 2021

What do we know about the SARS-CoV-2 vaccines so far?

A new study surveys what we know so far about SARS-CoV-2 vaccine candidates from advanced clinical trials.

27 Jan 2021

Antibodies and inflammatory markers may help identify COVID-19 cases and predict severity

A new preprint appearing on the medRxiv server describes the changes that occur in numerous antibodies and inflammatory molecules with age and at varying stages, or severity, of the infection and resulting illness. The results may help to predict the risk in individual cases.

26 Jan 2021

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

With the emergence of COVID-19 (coronavirus disease 2019), researchers have been closely investigating the complex interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the human immune system, and COVID-19 disease severity.

25 Jan 2021

Bispecific antibody shows efficacy against new SARS-CoV-2 variants

A team of international scientists has recently developed a bispecific antibody that can bind two non-overlapping regions of the spike receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and completely prevent the viral-host interaction.

25 Jan 2021

Infusion of convalescent blood plasma benefits patient with severe COVID-19

A 72-year-old woman was hospitalized with severe COVID-19 disease, 33 days after the onset of symptoms.

22 Jan 2021

Pfizer-BioNTech vaccine shows reduced neutralization potential against SARS-CoV-2 B.1.1.7 spike variant

Researchers in the UK have conducted a study assessing the efficacy of the Pfizer-BioNTech COVID-19 vaccine BNT162b2 against the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

21 Jan 2021

SARS-CoV-2 suppresses host innate immunity

SARS-CoV-2, the virus that causes COVID-19, blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues.

21 Jan 2021

South African SARS-CoV-2 variant escapes antibody neutralization

Researchers in South Africa have conducted a study showing that the novel 501Y.V2 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has emerged in the country is able to escape the neutralizing antibodies that are elicited by previously circulating strains of the virus.

20 Jan 2021

Mapping antibody reactivity in COVID-19 patients by using multi-coronavirus protein microarray

In an exciting, state-of-the-art study currently available on the medRxiv* preprint server, US researchers created a multi-coronavirus protein microarray containing full-length proteins, peptide libraries, and overlapping protein fragments from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as four other human coronaviruses.

19 Jan 2021

Immunoglobulin News and Research

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Researchers develop rapid COVID-19 diagnostic test affordable for low-income families

Previous SARS-CoV-2 infection may negate need for two vaccine doses

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

New platform for detecting and monitoring SARS-CoV-2 antibody responses

Fetal and neonatal therapy combination may lessen the aftereffects of congenital CMV infection

Moderna vaccine shows robust suppression of SARS-CoV-2 infection in animal model

What do we know about the SARS-CoV-2 vaccines so far?

Antibodies and inflammatory markers may help identify COVID-19 cases and predict severity

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

Bispecific antibody shows efficacy against new SARS-CoV-2 variants

Infusion of convalescent blood plasma benefits patient with severe COVID-19

Pfizer-BioNTech vaccine shows reduced neutralization potential against SARS-CoV-2 B.1.1.7 spike variant

SARS-CoV-2 suppresses host innate immunity

South African SARS-CoV-2 variant escapes antibody neutralization

Mapping antibody reactivity in COVID-19 patients by using multi-coronavirus protein microarray

Memory B cell response to SARS-CoV-2 evolves up to 6 months after infection, study finds

Study predicts good passive immunotherapy donors to combat COVID-19

Study sheds light on the causes of debilitating gut pain

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News